317P Survival analysis and prognostic factors in patients with metastatic breast cancer and oligometastatic disease

Abstract

generally preferred to continue the same systemic therapy after using SBRT for oligoprogressive and induced OMBC of initially polymetastatic disease irrespective of tumor subtypes, with the exception of SBRT for oligoprogressive triple-negative BC (TNBC) where the majority of respondents (55.8%) would change current therapy.Conclusions: Results of our survey showed discordance in the definition of OMBC. Even though a significant number of respondents would use SBRT for de novo OMBC, the vast majority preferred using SBRT after initial response to systemic therapy as compared to upfront SBRT. Respondents were more reluctant to use SBRT in TNBC compared with other tumor subtypes.Legal entity responsible for the study: Oncoalert Network.